The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
暂无分享,去创建一个
David M. Hyman | David S. Hong | Alberto S. Pappo | A. Drilon | G. Demetri | W. El-Deiry | D. Hyman | D. Hong | A. Pappo | D. Hawkins | S. Kummar | M. Brose | A. Dowlati | A. Farago | T. Laetsch | V. Boni | U. Lassen | Alexander Drilon | Shivaani Kummar | B. Turpin | George D. Demetri | Afshin Dowlati | Brian Turpin | Valentina Boni | Ramamoorthy Nagasubramanian | Scott Cruickshank | Wafik S. El-Deiry | S. DuBois | Theodore W. Laetsch | Steven G. DuBois | Anna F. Farago | Ulrik Lassen | Marcia S. Brose | Michael C. Cox | Nora Ku | Douglas S. Hawkins | S. Cruickshank | M. Cox | R. Nagasubramanian | N. Ku